Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (31-40 of 205) with videos related to

Pageof 21
Sort By:
Cell|November 18, 2017
First Approved Kinase Inhibitor for AMLJohn E J Rasko, Timothy P Hughes
Blood|April 25, 2022
Asciminib: a new therapeutic option in chronic-phase CML with treatment failureDavid T Yeung, Naranie Shanmuganathan, Timothy P Hughes
The New England Journal of Medicine|December 12, 2024
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. ReplyAndreas Hochhaus, Jorge E Cortes, Timothy P Hughes
Blood|November 3, 2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Susan Branford, Junia V Melo, Timothy P Hughes
Experimental Hematology|April 24, 2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine AStephen J Blake, Timothy P Hughes, A Bruce Lyons
Haematologica|June 26, 2025
Asciminib for Philadelphia chromosome-positive leukemiasTimothy P Hughes, Deborah L White, David T Yeung
Cancer|November 1, 2011
Suboptimal responses in chronic myeloid leukemia: implications and management strategiesElias Jabbour, Giuseppe Saglio, Timothy P Hughes, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Chronic myeloid leukemiaJunia V Melo, Timothy P Hughes, Jane F Apperley
Blood|January 6, 2025
The Evolution of Treatment-Free RemissionTimothy P Hughes, Agnes Sm Yong, David M Ross
Blood Advances|February 7, 2019
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKINaranie Shanmuganathan, Susan Branford, Timothy P Hughes, et al.
Pageof 21

Showing results (31-40 of 205) with videos related to

Sort By:
Pageof 21
Cell|November 18, 2017
First Approved Kinase Inhibitor for AMLJohn E J Rasko, Timothy P Hughes
Blood|April 25, 2022
Asciminib: a new therapeutic option in chronic-phase CML with treatment failureDavid T Yeung, Naranie Shanmuganathan, Timothy P Hughes
The New England Journal of Medicine|December 12, 2024
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. ReplyAndreas Hochhaus, Jorge E Cortes, Timothy P Hughes
Blood|November 3, 2009
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Susan Branford, Junia V Melo, Timothy P Hughes
Experimental Hematology|April 24, 2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine AStephen J Blake, Timothy P Hughes, A Bruce Lyons
Haematologica|June 26, 2025
Asciminib for Philadelphia chromosome-positive leukemiasTimothy P Hughes, Deborah L White, David T Yeung
Cancer|November 1, 2011
Suboptimal responses in chronic myeloid leukemia: implications and management strategiesElias Jabbour, Giuseppe Saglio, Timothy P Hughes, et al.
Hematology. American Society of Hematology. Education Program|November 25, 2003
Chronic myeloid leukemiaJunia V Melo, Timothy P Hughes, Jane F Apperley
Blood|January 6, 2025
The Evolution of Treatment-Free RemissionTimothy P Hughes, Agnes Sm Yong, David M Ross
Blood Advances|February 7, 2019
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKINaranie Shanmuganathan, Susan Branford, Timothy P Hughes, et al.
Pageof 21